The Illumina, Inc. (ILMN) Downgraded by Vetr Inc.

The Illumina, Inc. (ILMN) Downgraded by Vetr Inc.

ILMN has been the topic of several other reports. J P Morgan Chase & Co restated an “overweight” rating and issued a $250.00 price target on shares of Illumina in a research report on Wednesday. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Deutsche Bank AG restated a “hold” rating and issued a $175.00 price target (up from $165.00) on shares of Illumina in a report on Saturday, April 29th. Finally, Cantor Fitzgerald boosted their price target on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $174.38.

Illumina, Inc. (NASDAQ:ILMN) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday. They presently have a $202.18 price objective on the life sciences company’s stock. Vetr‘s target price would suggest a potential upside of 2.19% from the stock’s previous close.

Shares of Illumina (NASDAQ ILMN) traded up 14.83% on Wednesday, reaching $197.85. The company had a trading volume of 5,011,245 shares. The firm has a market capitalization of $28.89 billion, a PE ratio of 40.04 and a beta of 0.83. The company’s 50-day moving average is $174.66 and its 200 day moving average is $171.89. Illumina has a 12 month low of $119.37 and a 12 month high of $198.47.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The company had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.50% and a net margin of 18.13%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.86 EPS. Equities analysts forecast that Illumina will post $3.63 earnings per share for the current year.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $184.14, for a total value of $3,682,800.00. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $99,283,868.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Omead Ostadan sold 1,672 shares of the business’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $172.73, for a total transaction of $288,804.56. Following the completion of the sale, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at $4,532,780.66. The disclosure for this sale can be found here. Insiders have sold a total of 123,639 shares of company stock valued at $21,980,677 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Chevy Chase Trust Holdings Inc. boosted its position in shares of Illumina by 33.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 346,451 shares of the life sciences company’s stock valued at $59,114,000 after buying an additional 85,922 shares in the last quarter. Forte Capital LLC ADV boosted its stake in shares of Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares during the period. Gulf International Bank UK Ltd boosted its stake in shares of Illumina by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,040 shares of the life sciences company’s stock worth $7,685,000 after buying an additional 600 shares during the period. National Pension Service boosted its stake in shares of Illumina by 3.7% in the first quarter. National Pension Service now owns 122,352 shares of the life sciences company’s stock worth $21,186,000 after buying an additional 4,331 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares during the period. Hedge funds and other institutional investors own 93.68% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

To view Vetr’s full report, visit Vetr’s official website.

Related posts

Leave a Comment